Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Merck & Co., Inc. (MRK) Down, Could’ve Fallen Worse

Page 1 of 2

Merck & Co., Inc. (NYSE:MRK)Merck & Co., Inc. (NYSE:MRK)‘s stock was down almost 3% on Wednesday after the company released first quarter earnings.

Revenue dropped, but that was to be expected, with asthma-drug Singulair seeing generic competition. Every investor knew it was going to happen.

The problem was the other drugs didn’t make up nearly enough of the Singulair loss. In the fourth quarter — the first full quarter with generic competition — overall revenue fell only 4.5%, as Januvia and Gardasil closed some of the gap.

In the first quarter, revenue was down 9%. Changing currencies had a negative two percentage point affect on revenue, but even a 7% decline is still quite a fall. Investors were right to send Merck stock down.

Unlike the fourth quarter, Januvia, the company’s multi-billion diabetes drug franchise, not only didn’t help sales, but it actually contributed to the problem. Sales were down 1% in the first quarter. Merck & Co., Inc. (NYSE:MRK) blamed changing currencies for a two percentage point drop. It also blamed reduced inventories held by wholesalers in the U.S. According to Merck & Co., Inc. (NYSE:MRK), if wholesalers had kept product at the same level, it would have seen a 5% increase in U.S. sales instead of a 5% decline.

The question then becomes: Why did wholesalers reduce their inventory? Are they worried about competition from Bristol Myers Squibb Co. (NYSE:BMY) and AstraZeneca plc (ADR) (NYSE:AZN)‘s Onglyza, which is in the same DPP-4 class as Januvia? Or perhaps they think Johnson & Johnson (NYSE:JNJ)‘s newly approved diabetes drug Invokana, which is in a new class called SGLT2 inhibitors, will take away sales? Or maybe wholesalers are worried about recently reported side effects?

A lot of questions with few answers.

Management was adamant that they see SGLT2 inhibitors as a second-line treatment after DPP-4 drugs. That can’t give Pfizer Inc. (NYSE:PFE), which just struck a deal with Merck & Co., Inc. (NYSE:MRK) for its SGLT2 inhibitor, a warm and fuzzy feeling. But if Pfizer Inc. (NYSE:PFE)’s management was being honest, they’d probably agree. DPP-4 drugs have become the first-line branded treatment because of their high tolerability; SGLT2 drugs have a ways to go before doctors are comfortable prescribing them.

When pressed for more information about the inventory changes, Merck’s management basically blamed the decrease on a slowdown in growth of prescriptions, which are only growing at 4%. A year ago, Merck & Co., Inc. (NYSE:MRK) was still benefiting from safety concerns over Takeda‘s Actos and GlaxoSmithKline plc (ADR) (NYSE:GSK)‘s Avandia. With sales not accelerating, wholesalers can cut back on the inventory they hold.

I’m not sure that I fully buy that argument; U.S. sales of Onglyza were up 17% year over year in the first quarter, which wholesalers must be taking into consideration. But we’ll know in a quarter or two if sales slow down further.

Page 1 of 2